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Background. Asthma is a disorder characterized by a predominance of Th2 cells and eosinophilic inﬂammation. Suppressors of
cytokine signaling (SOCS) proteins act as negative regulators of cytokine signaling. In particular, SOCS1 and SOCS3 play an
important role in immune response by controlling the balance between Th1 and Th2 cells. In a previous study, we demonstrated
that treatment of chronic asthmatic mice with gene therapy using plasmid encoding galectin-3 (Gal-3) led to an improvement
in Th2 allergic inﬂammation. Methods. Using a microarray approach, this study endeavored to evaluate the changes produced by
therapeutic Gal-3 delivered by gene therapy in a well-characterized mouse model of chronic airway inﬂammation. Results were
conﬁrmed by real-time RT-PCR, Western blot and immunohistochemical analysis. Results. We identify a set of genes involved
in diﬀerent pathways whose expression is coordinately decreased/increased in mice treated with Gal-3 gene therapy. We report a
correlation between Gal-3 treatment and inhibition of SOCS1 and SOCS3 expression in lungs. Conclusion. These results suggest
that negative regulation of SOCS1 and 3 following Gal-3 treatment could be a valuable therapeutic approach in allergic disease.
1.Introduction
Asthma is a complex chronic disease characterized by
airway inﬂammation, airway hyperresponsiveness (AHR),
and reversible airway obstruction. In addition, structural
changescausingremodelingoccurasaresultofanimbalance
in the mechanisms behind lung tissue regeneration and
repair [1, 2].
Cytokines play an essential role in immune system reg-
ulation [3]. In both physiologic and pathologic conditions,
cytokine functions are strictly controlled. Cytokine signaling
pathways are negatively regulated by the so-called suppressor
of cytokine signaling (SOCS) family of proteins. SOCS
proteins not only act as simple negative-feedback regulators,
but are also involved in ﬁne-tuning the immune response
and in the cross-talk of the complicated cytokine signal
networks [4]. Since cytokines are constantly present in the
microenvironment of immune cells, signal regulation by
SOCS-family proteins must be important for the proper
progress, remission, and relapse of an immune response.
SOCS1, SOCS3, and SOCS5 therefore participate in CD4+
Th-cell diﬀerentiation and in Th1/Th2-cell balance [5]. Of
these, SOCS3 has been shown to inhibit IL-2 production
during T-cell activation, is predominantly expressed in Th2
cells, and inhibits Th1 diﬀerentiation [6–8]. Conversely,
SOCS5 is predominantly expressed in Th1 cells and inhibits
Th2 diﬀerentiation [9]. The data with respect to SOCS1 are
controversial; indeed, Fujimoto et al. showed that SOCS1
negatively regulates both Th1 and Th2 cell diﬀerentiation in
response to IL-12 and IL-4, respectively [10]. In contrast,
SOCS1 is a strong negative-feedback regulator of IFNγ,
and thus positively regulates Th17-cell diﬀerentiation by
suppressing the antagonistic eﬀect of IFNγ [4].
Gal-3 is an immunoglobulin IgE-binding protein which
belongs to a family of proteins that bind β-galactosides. It
has a unique amino-terminal domain, a highly conserved2 Mediators of Inﬂammation
repetitive sequence rich in proline and glycine, and a glob-
ular carboxyl-terminal domain containing the carbohydrate
recognition site. Gal-3 is expressed in a variety of tissues and
cell types [11].Inaddition,ithasbeenimplicatedindiﬀerent
processes, including inﬂammation and allergic pathologies
[12, 13]. We previously reported that administration of Gal-
3 by means of gene therapy inhibits asthmatic reactions by
downregulating IL-5 gene expression [14–16]. However, in a
complex pathology such as asthma, there are many factors
and pathways implicated, which is why we planned to study
more genes.
Genome-wide expression analysis with microarrays has
become a mainstay of genomics research [17, 18]. The
challengenolongerliesinobtaininggeneexpressionproﬁles,
but rather in interpreting the results to gain insights into
biological and molecular disease mechanism or identify gene
expression changes characteristic of diﬀerent diseases, or to
study the gene expression proﬁles, whose are aﬀected by
speciﬁc treatment. To overcome these analytical challenges,
several authors propose evaluating microarray data at the
gene-set level-based on prior biological knowledge [19].
In this study, we used cDNA microarrays to gain a
detailed molecular picture of the programmed responses of
theasthmaticmicetoGal-3genetherapy.Thetranscriptional
program was analyzed in lung samples from asthmatic mice
treated with Gal-3 and asthmatic mice that did not receive
the treatment. A set of pathways and genes was identiﬁed
by microarrays and then selected for further analysis by
RT-PCR, immunohistochemistry staining, and Western blot
to conﬁrm and explore their corresponding protein level.
Analysis of the transcriptional program reveals striking
evidenceofglobaldiﬀerencesbetweenmicetreatedwithGal-
3 and those that are not. The most prominent feature of the
gene signature identiﬁed in treated mice was a pattern of
reduced inﬂammatory genes and regulatory genes. SOCS1
and 3 were also among the inﬂammatory genes found to
be more abundant in asthmatic mice as compared to Gal-
3-treated mice. Accordingly, one of the new models of
therapy for allergic diseases could entail targeting SOCS3 by
using a Gal-3 gene therapy approach via inhibition of Th2
response. Such an immunomodulatory approach may have
the beneﬁcial eﬀect of balancing the immune system.
2.MaterialsandMethods
2.1. Animals and Development of Chronic Asthma by
Intranasal Administration of OVA and Gal-3 Gene Treatment.
All experimental procedures conformed to international
standards of animal welfare and were approved by the
Fundaci´ onJim´ enezD´ ıazAnimalResearchEthicsCommittee.
Male A/J mice (speciﬁc pathogen-free: 5 weeks old) were
purchased from Harlan Iberica.
Experimental protocols were performed as previously
reported [16]. The mice were placed in a small box and
anesthetized with inhaled Forane (Abbott, IL). The anes-
thetized mice inhaled 1mg/mL OVA (grade V; Sigma, St.
Louis, MO) intranasally. OVA was administered 3 days per
week for twelve weeks using a previously described method
[16].
Fourteen days after the ﬁrst OVA inhalation and once
every 15 days thereafter, the mice received intranasal
inhalations of 50μL of plasmid (1mg/mL) encoding Gal-3
(pEGFP-Gal-3, n = 20) or with plasmid without insert
(pEGFP, n = 15) or with saline (OVA, n = 15) as positive
controls. An additional negative control group was used in
which mice were injected with saline and exposed to saline
inhalation (SS, n = 10).
After instillation of plasmid into the lungs, Gal-3 was
detected by immunohistochemistry as previously reported
[16].
2.2. RNA Extraction and Microarray Hybridization. Twenty-
four hours after the last administration of antigen, the mice
were anesthetized and the lungs were removed. Total RNA
was isolated from the lungs using TRIzol Reagent (Life
Technologies, Paisley, UK) according to the manufacturer’s
protocol. Purity and integrity of the RNA was assessed
using an Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA, USA), and degraded samples were discarded.
Concentration was determined using a Nanodrop ND-
1000 spectrophotometer. A total of 5μgo fp u r i ﬁ e dR N A
samples was submitted to the Gene Expression Department
of Complutense University (Madrid, Spain) for labeling and
hybridization. In total, 19 samples were analyzed: six from
the OVA group, 8 from the pEGFP-Gal-3 group, and ﬁve
from the SS group. Following all appropriate protocols and
procedures for quality control, labeling, and fragmentation
of eukaryotic total RNA, the biotin-labeled cRNA samples
were hybridized to Mouse Genome 430 2.0 Microarrays
(Aﬀymetrix, Santa Clara, CA) according to manufacturer
protocols.
2.3. Microarray Data Analysis
2.3.1. Bioinformatics Analysis. Microarray analysis was per-
formed by the Bioinformatics Department of the Centro
de Investigaci´ on Pr´ ıncipe Felipe (Valencia, Spain) using
GEPAS version 3.1 (http://www.gepas.org/)[ 20]. Func-
tional analysis was carried out using the Babelomics suite
(http://www.babelomics.org/).
2.3.2. Preprocessing. Output data from the microarray nor-
malization process were preprocessed before micrroarray
analysis. Data were standardized using RMA [21]. Multiple
probes mapping to the same gene were merged using the
average as the summary of the hybridization values.
2.3.3. Diﬀerential Gene Expression. Diﬀerential gene expres-
sion was carried out using the Limma package from Bio-
conductor (http://www.bioconductor.org/)[ 22]. To account
for multiple testing eﬀects, P-values were corrected using the
false discovery rate [23].
2.3.4. Functional Analysis. FatiScan, a variant of the gene
set enrichment algorithm that detects signiﬁcant up- or
downregulatedblocksoffunctionallyrelatedgenesfromalist
of genes ordered by diﬀerential expression [24], was used toMediators of Inﬂammation 3
detect activations or deactivations in biological functions or
pathways. FatiScan is part of the Babelomics suite. FatiScan
can search blocks of genes that are functionally related by
diﬀerent criteria such as gene ontology terms or KEGG
pathways.
2.4. Real-Time RT-PCR. Quantitative real-time PCR was
performed for selected genes (SOCS-1, -3, -5, IL-10, and
TGF-β1) on a 7500 Real-Time PCR System (Applied
Biosystems, Warrington, UK). TaqMan PCR was performed
using a 20μL ﬁnal reaction volume containing 10μLo f
TaqMan Universal PCR Master Mix (Applied Biosystems,
Branchburg,NJ,USA),1μLof20XAssays-on-DemandGene
Expression Assay Mix, and 9μL of cDNA diluted in RNase-
free water. Each assay was performed in triplicate. The PCR
conditions used in all reactions were 2min at 50◦Ca n d
10min at 95◦C, with 40 two-step cycles (95◦Cf o r1 5 s
and 60◦C for 60s). Assays-on-Demand Gene Expression
primers speciﬁc for SOCS1, SOCS3, SOCS5, IL-10 and TGF-
β1 and rRNA (used as an endogen) were obtained from
Applied Biosystems (http://www.appliedbiosystems.com/).
The genes analyzed in this study were examined for
their relative expression by means of the ΔΔCT method
[25].
2.4.1. Western Blot Analysis. Lung lysates were prepared
in 20mM Tris-HCl, PH 8.0, 30mM Na4P2O7,4 0 m M
N a C l ,5m ME D T A ,1 %N P - 4 0 ,2m MN a 3VO4,a n d1m M
PMSF with a protease inhibitor cocktail (Sigma-Aldrich).
The lysates (10–20μg total protein) were resolved by SDS-
PAGE and analyzed by Western blotting. The blots were
incubatedfor60minwitha1:400dilutionofprimaryrabbit
anti-SOCS3 (Cell Signalling, Technology) or anti-β-actin
antibody. The secondary antibody, HRP-conjugated donkey
anti-rabbit IgG, was diluted 1:10000. Chemiluminescent
protein bands were detected by an ECL detection system
(Amersham Biosciences) according to the manufacturer’s
protocol.
2.5. Immunohistochemistry. The lungs were instilled with
neutral buﬀered Formalin in PBS, pH 7.2, the trachea
was tied oﬀ, and the lungs were immersed in Formalin
overnight. After ﬁxation, the lung tissues were embedded in
paraﬃn and cut into 6-μm-thick sections. Tissue sections
(6μm) were deparaﬃnized with xylene and dehydrated with
a series of graded alcohol solutions to automation buﬀer
(AB) consisting of 5% NaCl and 2% HCl (Biomeda, Foster
City, CA). Endogenous peroxidase was blocked in methanol
and 3% (vol/vol) H2O2 for 15min. After the sections were
washed twice, blocking was performed with BSA 4% and
normal goat serum 6% in PBS % 20min at 25◦C. The
slides were incubated with a primary rabbit anti-SOCS3
antibody (Cell Signalling, Tech) at 60μg/mL for 30min at
room temperature. For detection of SOCS3, a rabbit Elite kit
(Vector Laboratories, Burlingame, CA) was used as follows:
sections were washed twice with AB and then incubated
for 30min with a 1:400 dilution of biotinylated secondary
goat antirabbit IgG. Slides were washed again and incubated
with the Elite avidin-biotin complex (Vector Laboratories)
for 30min. For staining, slides were washed 5 times with
AB, and then the antibody complex was visualized using a
diaminobenzidine tablet (10mg; Sigma Chemical, St. Louis,
MO) dissolved in 20mL ofAB containing 12μL of 30%
H2O2 for 6min in the dark. All slides were then rinsed
in running tap water, counterstained with hematoxylin
( H a r e l c o ,G i b b s t o w n ,N J ) ,d e h y d r a t e dt h r o u g has e r i e so f
graded alcohols to xylene, and covered with a coverslip with
Permount (Fisher Scientiﬁc, Fair Lawn, NJ).
2.6. Statistical Analysis. The data from real-time RT-PCR
were expressed as geometric mean and standard deviation
(SD) values for a group size of 10–20 from three diﬀerent
experiments. Results were compared and evaluated using the
Kruskal-Wallis test and Dunn’s posttest multiple comparison
test. Statistical signiﬁcance was recognized at P ≤ .05.
Statistical analyses were performed using GraphPad InStat3
(GraphPad Software Inc., San Diego, CA, USA).
3. Results
3.1. Diﬀerential Gene Expression. We used microarrays to
proﬁle expression of over 37,169 genes in lung tissues from
six mice with asthma (OVA group), 8 mice treated with
plasmid encoding Gal-3 gene (pEGFP-Gal-3 group), and ﬁve
from the negative control group (SS group). Diﬀerentialgene
expressionineachgroupwascomparedwiththatobservedin
other groups. OVA mice exhibited higher mRNA expression
of TGF-β,SOCS-1,SOCS-3,IL17A,andIL17Fthanthatseen
in the pEGFP-GAL-3 mice. When comparing the pEGFP-
Gal-3 and the SS groups, only 2 genes were uprepresented
whilefortheOVAandtheSSgroups,977wereuprepresented
and 788 downrepresented (adjusted P-value <.05).
3.2. Gene Ontology. The FasScan test for gene set enrichment
analysis was applied to analyze the transcriptional proﬁles
of mice treated with pEGFP-Gal-3 versus the untreated
OVA group. We observed a signiﬁcant upregulation of
several biological processes and a downregulation of another
(adjusted P-value <.05, Figure 1)a tl e v e l4o fg e n eo n t o l o g y .
Additional analysis of gene biological function revealed
gene enrichment in several pathways. Interestingly, some of
these pathways presented an overexpression of core genes
in OVA mice and underexpression in Gal-3-treated mice
(SOCS, TGF-β, and IL-10). Table 1 shows the diﬀerentially
expressed genes within these functional categories.
3.3. Downregulation of SOCS1 and SOCS3 Gene Expression
by Gal-3 Treatment. Considering the results obtained by
microarray, we set out to discover whether Gal-3 treatment
aﬀected SOCS expression. SOCS1, SOCS3, and SOCS5 gene
expression levels were analyzed by real-time quantitative
PCR in lung tissue from mice groups.
When mice were treated for 12 weeks with Ag and
pEGFP-Gal-3, the relative level of SOCS1 and SOCS3 expres-
sion was signiﬁcantly lower than it was in OVA-exposed
mice without gene treatment: 1.103 versus 5.69 P<. 0014 Mediators of Inﬂammation
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Figure 1: Biological pathway up- and downregulated in OVA versus pEGFP-GAL. Red indicates the biological processes overrepresented in
the OVA group (percentage >50), and blue indicates that these pathways are overrepresented in the pEGFP-Gal-3 group (percentage <50).
Table 1: Genes included in upregulated gene ontology pathways in OVA versus pEGFP-GAL 3 comparison.
Biological process (GO database) Genes
Inﬂammatory response IDO1, IL17A, IL17B, IL17F, IL1A, IL25, TGFB1, IL6, IL4, FOXP3, JAK2, STAT5A, TLR4
Regulation of immunoglobulin
mediated immune response B C L 6 ,F O X P 3 ,F C G 2 B ,I G H 7 ,T N F ,TGFB1, IL4, STAT6, IGH1A, IGH3, IGH7, C3, IL27RA
Negative regulation of
inﬂammatory response IL10, FOXP3, TGFB, SOCS3, IL2, TNF1B, AD, FOXF1A, IL2RA, ZFP36
Cytokine biosynthetic process ADAM3, GATA3, IGF2BP1, IL12B, MAP2K3, IL6, FOXP3, IL-10, NFKB1, BCL3, INFG, IL1B, TNF,
WNT5A, IL21, IL1A, STAT5, IL17F
T-cell-mediated immunity IL4RA, BCL6, TGFB, IL20RB, IL2RA, IDO, FOXP3, CD27, CD74, LAG3, CASP3
Cytokine and chemokine
mediated signalling pathway
ILR1, IL23R, IL2RB, IL3, IL5, JAK1, JAK3, SOCS1, SOCS3, SOCS5,S T A T 1 ,STAT3,S T A T 5 A ,
STAT5B, IL6, IL6RA, TNF
Leukocyte degranulation P4K2A, RAB27A, IGH7, HMOX1, FOXF1A, FCER1A, FCER1G, PRAM1
GO: Gene Ontology.
and 1.14 versus 3.47 P<. 01, respectively, representing
nearly 80.6% and 67.15% inhibition (Figures 2(a) and 2(b)).
However,treatmentwithemptyplasmiddidnotsigniﬁcantly
modifySOCSexpressionincomparisonwiththeOVAgroup.
Moreover, statistically signiﬁcant diﬀerences were observed
upon comparing groups treated with empty plasmid and
plasmid-encoding Gal-3 in SOCS1 and SOCS3 expression,
respectively (P<. 01).
There was no signiﬁcant change in the levels of SOCS5
gene expression (Figure 2(c)).
3.4. Forced Gal-3 Expression by Gene Therapy Inhibits SOCS3
Protein Expression. To ascertain whether the same eﬀect
w a so b s e r v a b l ei np r o t e i ne x p r e s s i o n ,w ep e r f o r m e da
Western blot analysis in lung tissue using an anti-SOCS3
antibody. As depicted in Figure 3(a), higher SOCS3 protein
expression was detected in the lungs of the OVA group
of mice. The pEGFP-Gal-3 and SS groups showed low
constitutive expression of SOCS3. Figure 3(b) shows SOCS3
protein expression quantiﬁed by densitometry and normal-
ized by β-actin. The results indicate that SOCS3 was moreMediators of Inﬂammation 5
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Figure 2: Semiquantitative expression of SOCS1, SOCS3, and SOCS5 genes in lungs after twelve weeks of OVA exposure. Relative mRNA
levelsofSOCS1(a),SOCS3(b),andSOCS5(c)geneexpressioninlungsofdiﬀerentgroupsofmiceweredeterminedbyreal-timequantitative
PCR. Values were normalized with rRNA gene used as endogen. Black bars represent the OVA group (n = 15), white bars the pEGFP group
(n = 15), shaded bars the pEGFP-Gal-3 group (n = 20), and gray bars the SS group (n = 10). The results show relative gene expressions,
as determined by the ΔΔCT method, after twelve weeks of antigen exposure. Signiﬁcant diﬀerences in SOCS3 and SOCS1 (∗∗P<. 01 and
∗∗∗P<. 001) expression levels were obtained for the pEGFP-Gal-3 versus the OVA and pEGFP groups.
strongly expressed in the lungs of asthmatic mice than
in the plasmid encoding Gal-3 gene and negative control
mice.
3.5. Accumulation of SOCS3-Expressing Cells in the Lungs of
Asthmatic Mice Is Inhibited by Gal-3. Accordingly, immuno-
histochemical analysis was then used to examine SOCS3
protein expression at the inﬂammatory site. In the OVA- and
pEGFP-treated mice, SOCS3-expressing cells were present in
high numbers at the inﬂammatory site (Figures 4(b) and
4(c))andinairwayepithelialcells.WhereastheGal-3-treated
mice displayed no SOCS3-expressing cells (Figure 4(d)), the
appearance of the lungs was similar to that of the control
mice (Figure 4(a)).6 Mediators of Inﬂammation
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Figure 3: Western blot of SOCS3. (a) Protein extract from lungs
was separated by 12% SDS-PAGE and blotted onto nitrocellulose
membranes. Detection of SOCS3 was performed with goat anti-
mouseIgG.Actinwasusedastheinternalcontrol.(b)SOCS3bands
were quantiﬁed by densitometry and corrected by actin expression.
DensitometricanalysisrevealsastrongexpressionofSOCS3protein
in the OVA group, compared with the pEGFP-Gal-3 and SS groups.
Data are expressed as the geometric mean ± SD, n = 4, ∗P<. 05.
3.6. SOCS1 and SOCS3 Aﬀect Production of Both IL-10
and TGF-β1 after Gene Inhibition with Gal-3. Activated T
cells migrate to the lungs and release inﬂammatory and
regulatory cytokines to orchestrate the allergic response.
Given the diﬀerential SOCS3 expression in groups of mice
(Gal-3-treated versus OVA), we predicted that regulatory
cytokines would be aﬀected by the relatively low levels
of SOCS1 and SOCS3 expression in Gal-3-treated mice.
We, therefore, assessed the eﬀect of Gal-3 gene therapy
on regulatory cytokine levels (IL-10 and TGF-β1)i nl u n g s
after 12 weeks of chronic OVA-challenge. When the mice
were treated for twelve weeks with antigen and pEGFP-
Gal-3, the relative level of IL-10 and TGF-β1 expression
was signiﬁcantly lower than it was among OVA-exposed
mice without gene treatment: 1.2 versus 4.4 and 1.4 versus
10.5 P<. 001, representing nearly 72.72% and 86.60%
inhibition, respectively (Figure 5). However, treatment with
empty plasmid did not signiﬁcantly modify IL-10 and TGF-
β1 expression compared to the OVA group.
4. Discussion
The present study used microarray technology to deﬁne the
patterns of expression associated with Gal-3 gene therapy in
lungs of asthmatic mice. In particular, we compared gene
expression in lungs from OVA and pEGFP-Gal-3 groups. We
identiﬁed a “Gal-3 treated signature” gene-expression proﬁle
that was induced in the OVA mouse lung by exposure to
Gal-3. This signature proﬁle included several genes related
to lung development, inﬂammatory response, and so forth.
Oneofthemostimportantﬁndingsofthisstudyisthefailure
to identify a sole induced gene despite the fact that several
pathways were indeed induced or underregulated. This is not
surprising because asthma is a complex disease with many
factors.
Traditional strategies for gene expression analysis have
focused on identifying individual genes that exhibit dif-
ferences between two states of interest. Although useful,
they fail to detect complex biological processes that are
distributed across a network of genes and are subtle at the
level of individual genes. Also, high variability between mice
and limited sample sizes make it diﬃcult to distinguish
gene diﬀerences. Thus, an analytical strategy, Gene Set
Enrichment Analysis, has been designed to detect coordinate
changes in the expression of groups of functionally related
genes [25].
The analysis of gene biological function revealed gene
enrichment in several pathways when comparing the
OVA and pEGFP-Gal-3 groups. Interestingly, inﬂammatory
response, leukocyte activation, and cytokine production
processes presented a signiﬁcant overexpression in mice
from the OVA group compared to mice treated with
Gal-3 gene therapy. These data were consistent with our
previous results [16]. One of the pathways that underwent
signiﬁcant enrichment in OVA mice in comparison to
the pEGFP-GAL-3 mice group were the processes impli-
cated in negative regulation of inﬂammatory response.
Prominent among this class of intracellular regulators
are members of the SOCS family of proteins [3, 26].
Signiﬁcant interest in the SOCS family stems from the
belief that SOCS proteins may integrate multiple cytokine
signals and mediate cross-communication between antag-
onistic cytokines produced by diﬀerent cells through their
inhibitory eﬀects on cytokine receptors and signaling
molecules.
SOCS proteins exercise negative regulation for many
aspects of cytokine signaling. Hence, some members of the
SOCS protein family (SOCS1, 3 and 5) participate in the
regulation of Th1/Th2 balance [27, 28].
We conﬁrmed microarray data using real-time quan-
titative PCR, demonstrating that mice treated with Ag
and pEGFP-Gal-3 showed signiﬁcantly lower levels of
SOCS1 and SOCS3 expression than OVA-exposed mice not
receiving gene treatment. These data are in concordanceMediators of Inﬂammation 7
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Figure 4: Immunohistochemical expression of SOCS-3 in lung tissue from A/J mice. (a) Saline control group (untreated). (b) Positive
control group (OVA group) with chronic allergic airway inﬂammation. (c) pEGFP group, OVA immunized animals treated with empty
plasmid. (d) pEGFP-Gal-3 group, OVA immunized animals treated with plasmid encoding Gal-3. (e) Control using normal goat IgG instead
of goat anti-SOCS3 antibody. The picture is a representative example of 5 mice, all displaying similar results.
with other studies described in the literature in which
no diﬀerences were found in SOCS5 gene-expression lev-
els between healthy patients and those with asthma or
atopic dermatitis. Nevertheless, SOCS3 expression levels
are high in T cells from patients with this allergic disease
[29].
In the group of mice receiving plasmid with Gal-3 gene
by intranasal administration, we obtained values similar in
SOCS3 and SOCS1 gene expression to those of the healthy
group and lower than those of the other two groups of
asthmatic mice that had not received pEGFP-Gal-3. This
suggests that gal-3 may be exercising some direct or indirect
eﬀect on the transcription of the genes of SOCS3 and
SOCS1.
The impact of gal-3 therapy on SOCS3 was further
conﬁrmed by Western blot and by immunohistochemical
analysis. Accumulation of SOCS3-expressing cells at the
inﬂammatory site coincides with accumulation of inﬂam-
matory cells. In the mice treated with Gal-3, however, there
was a correlation between non-SOCS3-expressing cells and
absence of inﬂammatory cells, probably due to the fact that
SOCS3ispredominantlyexpressedinTh2cells.Theseresults
suggest that migration of SOCS3-expressing cells may be
implicated in the development and exacerbation of lung
inﬂammation, therefore suggesting that downregulation of
SOCS3 expression by Gal-3 inhibits development of lung
inﬂammation. In brief, the protein expression results were
similar to those yielded by gene expression analysis.
Activated T cells migrate to the lungs and release
inﬂammatory and regulatory cytokines to orchestrate the
allergic response. We, therefore, assessed the eﬀect of Gal-3
gene therapy on lung regulatory cytokine levels (IL-10
and TGF-β1) after 12 weeks of chronic OVA-challenge.
Our results indicated that IL-10 and TGF-β1 may be
intermediary cytokines involved in SOCS3 expression. Also
appearing in Table 1 are IL17A, IL17B, IL17F, TGFB1,
FOXP3, IL10, SOCS3, SOCS1, SOCS5, and STAT3 as genes
that are up-regulated in Gene Ontology pathways in OVA
versus pEGFP-GAL 3 mice, all of which are implicated
in regulatory immune response. In a ﬁnding similar to
ours, McGee et al. observed that the therapeutic eﬀect of
FMS-like tyrosine kinase 3 (Flt3) in reversing the hall-
marks of allergic asthma in a mouse model is mediated
by decreasing TGF-β, which in turn decreases Th17 cells
and the expression of SOCS1 and SOCS3 in the lung
of asthmatic mice [30]. Also, there is increasing evidence
showing that IL-10 induces SOCS3 gene expression through
theactivationofSTAT3,whichactivatestheSOCS3promoter
[31].
This study demonstrates that SOCS proteins are impli-
cated in the mechanism whereby Th2 allergic asthma is
inhibited by Gal-3. The role of Gal-3 in TH1/Th2 immune8 Mediators of Inﬂammation
∗∗P<. 01
∗∗∗P<. 001
0
2
4
6
8
R
e
l
a
t
i
v
e
m
R
N
A
e
x
p
r
e
s
s
i
o
n
o
f
I
L
-
1
0
(a)
∗∗P<. 01
∗∗∗P<. 001
0
2
4
6
8
10
12
14
R
e
l
a
t
i
v
e
m
R
N
A
e
x
p
r
e
s
s
i
o
n
o
f
T
G
F
-
β
1
(b)
Figure 5: Eﬀect of Plasmid with Gal-3 on Quantitative Expression of Cytokine Genes in lungs after Twelve Weeks of OVA Exposure. Relative
mRNA levels of IL-10 (a) and TGF-β1(b) gene expression in lungs from diﬀerent groups of mice were determined by real-time quantitative
PCR. Values were normalized with the rRNA gene used as an endogen. Black bars represent the OVA group (geometric mean ± SD, n = 15),
white bars the pEGFP group (geometric mean ± SD, n = 15), shaded bars the pEGFP-Gal-3 group (geometric mean ± SD, n = 20), and
gray bars the SS group (geometric mean ± SD, n = 10). The results show relative gene expressions, as determined by the ΔΔCT method,
after twelve weeks of antigen exposure. Signiﬁcant diﬀerences in IL-10 and TGF-β1 (∗∗∗P<. 001) expression levels were obtained for the
pEGFP-Gal-3 versus the OVA and pEGFP groups. In the case of empty plasmid, no signiﬁcant diﬀerences were found with respect to the
OVA group.
and inﬂammatory responses appearsto vary according to the
experimental models used (administration of Gal-3 versus
Gal-3 null animals) [15, 16, 32]. We provide evidence of
a correlation between treatment with Gal-3 and inhibition
of SOCS1 and SOCS3 expression in lungs. These results
suggest that negative regulation of SOCS1 and 3 by Gal-3
treatment could be a good therapeutic approach in allergic
diseases.
Accordingly,oneofthenewmodelsoftherapyforallergic
diseases could entail targeting SOCS3 by using a Gal-3
gene therapy approach via inhibition of Th2 response. Such
an immunomodulatory approach may have the beneﬁcial
eﬀect of controlling the appropriate balance of the immune
system.
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